SVG 103
Alternative Names: SVG-103Latest Information Update: 28 Aug 2024
At a glance
- Originator SoVarGen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Neurodevelopmental disorders
Most Recent Events
- 28 Aug 2024 Phase-II clinical trials in Neurodevelopmental disorders (Parenteral) (SoVarGen pipeline, August 2024)
- 08 Sep 2022 SVG 103 is available for licensing as of 08 Sep 2022. http://www.sovargen.com/rd#section1
- 08 Sep 2022 Early research in Neurodevelopmental disorders in South Korea (unspecified route) prior to September 2022 (SoVarGen pipeline, September 2022)